Senti Biosciences is trading 5.44% down now at $0.41, amid sector-driven biotech weakness.
- It fell 5.83% to $0.44 on August 20.
- No new company-specific announcement was identified for August 21; recent coverage instead points to sector-driven weakness.
- Biotech is down 2.47% during regular trading as investors take profits after the Moderna-driven rally and broader biotech recovery; the latest reported quarterly loss was $12.75 million.